Approach Considerations

The decision to provide thromboprophylaxis to pregnant patients depends on the following:

Any prior personal history of VTE
The presence of high- versus low-risk thrombophilia
The setting in which a prior VTE occurred (pregnancy/estrogen-related, idiopathic, or in the setting of nonrecurrent risk factors such as fractures, surgery, or immobilization)

These factors affect the decision to provide prophylaxis, as well as the timing (antenatal or postpartum only) and intensity of therapy. Early recognition of risk factors and wide implementation of thromboprophylaxis guidelines in the UK found a significant decrease in their maternal mortality due to thromboembolisms.^[57]

The following recommendations are based on the table from ACOG Practice Bulletin 123, Published September 2011 (reaffirmed in 2014):^[58]

Table 2. Management of Pregnancy in a Patient With a History of VTE (Open Table in a new window)

Clinical Scenario	Antepartum Management	Postpartum Management
Low-risk thrombophilia without prior VTE	Surveillance without anticoagulation or prophylactic LMWH or UFH	Surveillance without anticoagulation OR postpartum anticoagulation in the presence of additional risk factors (eg, obesity, prolonged immobility, first-degree relative with VTE before age 50 years)
Low-risk thrombophilia with a single episode of VTE in a patient not receiving long-term anticoagulation therapy	Prophylactic or intermediate LMWH/UFH or surveillance without anticoagulation therapy	Anticoagulation therapy or intermediate-dose LMWH/UFH
High-risk thrombophilia (antithrombin deficiency, homozygous factor V Leiden, homozygous prothrombin mutation G20210A, double heterozygous factor V Leiden and prothrombin mutation G20210A) without prior VTE	Prophylactic LMWH or UFH	Anticoagulation therapy
High-risk thrombophilia with previous single episode of VTE in a patient not receiving long-term anticoagulation therapy	Prophylactic-, intermediate-dose, or adjusted-dose LMWH or UFH	Anticoagulation therapy or intermediate- or adjusted-dose LMWH/UFH for 6 weeks
No thrombophilia with single prior episode of VTE with a transient risk factor no longer present and VTE not associated with pregnancy- or estrogen-related risk factor	Surveillance without anticoagulation	Anticoagulation therapy
No thrombophilia with single prior episode of VTE associated with transient risk factor associated with pregnancy or estrogen related	Prophylactic-dose LMWH/UFH	Anticoagulation therapy
No thrombophilia with single prior episode VTE without associated risk factor in a patient not receiving long-term anticoagulation therapy	Prophylactic-dose LMWH/UFH	Anticoagulation therapy
Thrombophilia or no thrombophilia with 2 or more VTE episodes in a patient not receiving long-term anticoagulation therapy	Prophylactic or therapeutic dose of either LMWH or UFH	Anticoagulation therapy or therapeutic dose LMWH/UFH for 6 weeks
Thrombophilia or no thrombophilia with 2 or more VTE episodes in a patient receiving long-term anticoagulation therapy	Therapeutic dose of either LMWH or UFH	Resumption of long-term anticoagulation therapy
Abbreviations: LMWH, low molecular weight heparin; UFH, unfractionated heparin

A systematic review by Croles et al reported that antepartum or postpartum thrombosis prophylaxis, or both should be considered for women with antithrombin, protein C, or protein S deficiency or with homozygous factor V Leiden. Thrombosis prophylaxis on the basis of thrombophilia and family history alone should generally not be prescribed for women with heterozygous factor V Leiden, heterozygous prothrombin G20210A mutation, or compound heterozygous factor V Leiden and prothrombin G20210A.^[59]

Consultations

Consider consultation with a maternal fetal medicine specialist and/or hematologist.

Long-Term Monitoring

Postpartum therapeutic and prophylactic management of VTE is as listed above.

Estrogen-containing contraception has been shown to increase the risk of VTE 35-99 times above baseline.^[60]Therefore, estrogen-based contraception is contraindicated in a patient with a history of VTE or thrombophilia. Nonetheless, screening all women prior to initiating estrogen-containing contraception is not recommended by the ACOG.^[61]Contraceptive methods, including progestin-containing contraceptives, may be considered in women with a prior VTE or known thrombophilia.^[19]

Medication

Creanga AA, Berg CJ, Syverson C, Seed K, Bruce FC, Callaghan WM. Pregnancy-related mortality in the United States, 2006-2010. Obstet Gynecol. 2015 Jan. 125 (1):5-12. [QxMD MEDLINE Link].
Chang J, Elam-Evans LD, Berg CJ, et al. Pregnancy-related mortality surveillance--United States, 1991--1999. MMWR Surveill Summ. 2003 Feb 21. 52(2):1-8. [QxMD MEDLINE Link].
Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ 3rd. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005 Nov 15. 143(10):697-706. [QxMD MEDLINE Link].
Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008 Apr. 6(4):632-7. [QxMD MEDLINE Link].
Andersen BS, Steffensen FH, Sørensen HT, Nielsen GL, Olsen J. The cumulative incidence of venous thromboembolism during pregnancy and puerperium--an 11 year Danish population-based study of 63,300 pregnancies. Acta Obstet Gynecol Scand. 1998 Feb. 77(2):170-3. [QxMD MEDLINE Link].
Gherman RB, Goodwin TM, Leung B, Byrne JD, Hethumumi R, Montoro M. Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. Obstet Gynecol. 1999 Nov. 94(5 Pt 1):730-4. [QxMD MEDLINE Link].
Lindqvist P, Dahlbäck B, Marsál K. Thrombotic risk during pregnancy: a population study. Obstet Gynecol. 1999 Oct. 94(4):595-9. [QxMD MEDLINE Link].
Simpson EL, Lawrenson RA, Nightingale AL, Farmer RD. Venous thromboembolism in pregnancy and the puerperium: incidence and additional risk factors from a London perinatal database. BJOG. 2001 Jan. 108(1):56-60. [QxMD MEDLINE Link].
Jacobsen AF, Skjeldestad FE, Sandset PM. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium--a register-based case-control study. Am J Obstet Gynecol. 2008 Feb. 198(2):233.e1-7. [QxMD MEDLINE Link].
Liu S, Rouleau J, Joseph KS, et al. Epidemiology of pregnancy-associated venous thromboembolism: a population-based study in Canada. J Obstet Gynaecol Can. 2009 Jul. 31(7):611-20. [QxMD MEDLINE Link].
James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol. 2006 May. 194(5):1311-5. [QxMD MEDLINE Link].
Pabinger I, Grafenhofer H, Kyrle PA, et al. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood. 2002 Aug 1. 100(3):1060-2. [QxMD MEDLINE Link].
James AH, Tapson VF, Goldhaber SZ. Thrombosis during pregnancy and the postpartum period. Am J Obstet Gynecol. 2005 Jul. 193(1):216-9. [QxMD MEDLINE Link].
James AH. Venous thromboembolism in pregnancy. Arterioscler Thromb Vasc Biol. 2009 Mar. 29(3):326-31. [QxMD MEDLINE Link].
Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb. 141 (2 Suppl):e691S-736S. [QxMD MEDLINE Link].
Greer IA. The challenge of thrombophilia in maternal-fetal medicine. N Engl J Med. 2000 Feb 10. 342(6):424-5. [QxMD MEDLINE Link].
Marik PE, Plante LA. Venous thromboembolic disease and pregnancy. N Engl J Med. 2008 Nov 6. 359(19):2025-33. [QxMD MEDLINE Link].
Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol. 2006 Jan. 132(2):171-96. [QxMD MEDLINE Link].
American College of Obstetricians and Gynecologists Practice Bulletin No 124. Inherited thrombophilias in pregnancy. Obstet Gynecol. 2011.
Said JM, Higgins JR, Moses EK, et al. Inherited thrombophilia polymorphisms and pregnancy outcomes in nulliparous women. Obstet Gynecol. 2010 Jan. 115(1):5-13. [QxMD MEDLINE Link].
Simcox LE, Ormesher L, Tower C, Greer IA. Thrombophilia and Pregnancy Complications. Int J Mol Sci. 2015 Nov 30. 16 (12):28418-28. [QxMD MEDLINE Link].
Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. 2005 Apr 18. CD002859. [QxMD MEDLINE Link].
Bremme KA. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol. 2003 Jun. 16(2):153-68. [QxMD MEDLINE Link].
McLean KC, Bernstein IM, Brummel-Ziedins KE. Tissue factor-dependent thrombin generation across pregnancy. Am J Obstet Gynecol. 2012 Aug. 207 (2):135.e1-6. [QxMD MEDLINE Link].
Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis. Hum Genet. 2001 Oct. 109(4):369-84. [QxMD MEDLINE Link].
Biron-Andreani C, Schved JF, Daures JP. Factor V Leiden mutation and pregnancy-related venous thromboembolism: what is the exact risk? Results from a meta-analysis. Thromb Haemost. 2006 Jul. 96(1):14-8. [QxMD MEDLINE Link].
Zotz RB, Gerhardt A, Scharf RE. Inherited thrombophilia and gestational venous thromboembolism. Best Pract Res Clin Haematol. 2003 Jun. 16(2):243-59. [QxMD MEDLINE Link].
Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med. 2000 Feb 10. 342(6):374-80. [QxMD MEDLINE Link].
Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost. 1995 Jan. 73(1):151-61. [QxMD MEDLINE Link].
Federman DG, Kirsner RS. An update on hypercoagulable disorders. Arch Intern Med. 2001 Apr 23. 161(8):1051-6. [QxMD MEDLINE Link].
Martinelli I, De Stefano V, Taioli E, Paciaroni K, Rossi E, Mannucci PM. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost. 2002 May. 87(5):791-5. [QxMD MEDLINE Link].
Dykes AC, Walker ID, McMahon AD, Islam SI, Tait RC. A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol. 2001 Jun. 113(3):636-41. [QxMD MEDLINE Link].
Goodwin AJ, Rosendaal FR, Kottke-Marchant K, Bovill EG. A review of the technical, diagnostic, and epidemiologic considerations for protein S assays. Arch Pathol Lab Med. 2002 Nov. 126(11):1349-66. [QxMD MEDLINE Link].
Friederich PW, Sanson BJ, Simioni P, et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med. 1996 Dec 15. 125(12):955-60. [QxMD MEDLINE Link].
Paidas MJ, Ku DH, Lee MJ, et al. Protein Z, protein S levels are lower in patients with thrombophilia and subsequent pregnancy complications. J Thromb Haemost. 2005 Mar. 3(3):497-501. [QxMD MEDLINE Link].
Carraro P. Guidelines for the laboratory investigation of inherited thrombophilias. Recommendations for the first level clinical laboratories. Clin Chem Lab Med. 2003 Mar. 41(3):382-91. [QxMD MEDLINE Link].
De Stefano V, Leone G, Mastrangelo S, et al. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost. 1994 Jun. 71(6):799-800. [QxMD MEDLINE Link].
Conard J, Horellou MH, Van Dreden P, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost. 1990 Apr 12. 63(2):319-20. [QxMD MEDLINE Link].
De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med. 1999 Sep 9. 341(11):801-6. [QxMD MEDLINE Link].
Franchini M, Veneri D, Salvagno GL, Manzato F, Lippi G. Inherited thrombophilia. Crit Rev Clin Lab Sci. 2006. 43(3):249-90. [QxMD MEDLINE Link].
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb. 4(2):295-306. [QxMD MEDLINE Link].
Khamashta MA, Cuadrado MJ, Mujic F, Tub NA, Hunt BJ, Hughs GR. The management of thrombosis in the anti-phospholipid antibody syndrome. N Engl J Med. 1995. 322:993-997.
Brey RL, Hart RG, Sherman DG, Tegeler CH. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology. 1990 Aug. 40(8):1190-6. [QxMD MEDLINE Link].
Ferro D, Quintarelli C, Rasura M, Antonini G, Violi F. Lupus anticoagulant and the fibrinolytic system in young patients with stroke. Stroke. 1993 Mar. 24(3):368-70. [QxMD MEDLINE Link].
Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA. 2006 Mar 1. 295(9):1050-7. [QxMD MEDLINE Link].
Lima F, Khamashta MA, Buchanan NM, Kerslake S, Hunt BJ, Hughes GR. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol. 1996 Mar-Apr. 14(2):131-6. [QxMD MEDLINE Link].
Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol. 1992 Oct. 80(4):614-20. [QxMD MEDLINE Link].
Branch DW, Khamashta MA. Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet Gynecol. 2003 Jun. 101(6):1333-44. [QxMD MEDLINE Link].
Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost. 2005 Feb. 3(2):292-9. [QxMD MEDLINE Link].
Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med. 1999 Jan 7. 340(1):9-13. [QxMD MEDLINE Link].
Peng F, Labelle LA, Rainey BJ, Tsongalis GJ. Single nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene are common in US Caucasian and Hispanic American populations. Int J Mol Med. 2001 Nov. 8(5):509-11. [QxMD MEDLINE Link].
McColl MD, Ellison J, Reid F, Tait RC, Walker ID, Greer IA. Prothrombin 20210 G-->A, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy. BJOG. 2000 Apr. 107(4):565-9. [QxMD MEDLINE Link].
Goodman C, Goodman CS, Hur J, Jeyendran RS, Coulam C. The association of Apoprotein E polymorphisms with recurrent pregnancy loss. Am J Reprod Immunol. 2009 Jan. 61(1):34-8. [QxMD MEDLINE Link].
Santacroce R, Sarno M, Cappucci F, et al. Low protein Z levels and risk of occurrence of deep vein thrombosis. J Thromb Haemost. 2006 Nov. 4(11):2417-22. [QxMD MEDLINE Link].
Goodwin AJ, Rosendaal FR, Kottke-Marchant K, Bovill EG. A review of the technical, diagnostic, and epidemiologic considerations for protein S assays. Arch Pathol Lab Med. 2002 Nov. 126(11):1349-66. [QxMD MEDLINE Link].
Girling J, de Swiet M. Inherited thrombophilia and pregnancy. Curr Opin Obstet Gynecol. 1998 Apr. 10(2):135-44. [QxMD MEDLINE Link].
Barbour LA, Oja JL, Schultz LK. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol. 2004 Sep. 191 (3):1024-9. [QxMD MEDLINE Link].
James A. ACOG Practice bulletin no. 123: thromboembolism in pregnancy. Obstet Gynecol. 2011 Sep. 118(3):718-29. [QxMD MEDLINE Link].
Croles FN, Nasserinejad K, Duvekot JJ, Kruip MJ, Meijer K, Leebeek FW. Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian meta-analysis. BMJ. 2017 Oct 26. 359:j4452. [QxMD MEDLINE Link].
Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med. 2004 Oct 11. 164(18):1965-76. [QxMD MEDLINE Link].
ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006 Jun. 107(6):1453-72. [QxMD MEDLINE Link].
ACOG Practice Bulletin No. 102: management of stillbirth. Obstet Gynecol. 2009 Mar. 113(3):748-61. [QxMD MEDLINE Link].
Farahmand K, Totonchi M, Hashemi M, et al. Thrombophilic genes alterations as risk factor for recurrent pregnancy loss. J Matern Fetal Neonatal Med. 2015 Jul 6. 1-5. [QxMD MEDLINE Link].
Ziakas PD, Poulou LS, Pavlou M, Zintzaras E. Thrombophilia and venous thromboembolism in pregnancy: a meta-analysis of genetic risk. Eur J Obstet Gynecol Reprod Biol. 2015 Aug. 191:106-11. [QxMD MEDLINE Link].

Media Gallery

of 0

Table 1. Pregnancy Complications Associated with Thrombophilia ^{[21, 18]}

Thrombophilia	First-Trimester Loss	Late Fetal Loss	Preeclampsia	Abruption	Fetal Growth Restriction
Factor V Leiden, homozygous	2.71 (1.32-5.58)*	1.98 (0.4-9.69)	1.87 (0.44-7.88)	8.43 (0.41-171.20)	4.64 (0.19-115.68)
Factor V Leiden, heterozygous	1.68 (1.09-2.58)*	2.06 (1.1-3.86)*	2.19 (1.46-3.27)*	4.70 (1.13-19.59)*	2.68 (0.59-12.13)
Prothrombin, heterozygous	2.49 (1.24-5.00)*	2.66 (1.28-5.53)*	2.54 (1.52-4.23)*	7.71 (3.01-19.76)*	2.92 (0.62-13.70)
MTHFR C677T, homozygous	1.40 (0.77-2.55)	1.31 (0.89-1.91)	1.37 (1.07-1.76)*	1.47 (0.40-5.35)	1.24 (0.84-1.82)
Antithrombin deficiency	0.88 (0.17-4.48)	7.63 (0.3-196.36)	3.89 (0.16-97.19)	1.08 (0.06-18.12)	N/A
Protein C deficiency	2.29 (0.20-26.43)	3.05 (0.24-38.51)	5.15 (0.26-102.22)	5.93 (0.23-151.58)	N/A
Protein S deficiency	3.55 (0.35-35.72)	20.09 (3.7-109.15)*	2.83 (0.76-10.57)	2.11 (0.47-9.34)	N/A
Anticardiolipin antibodies	3.40 (1.33-8.68)*	3.30 (1.62-6.70)*	2.73 (1.65-4.51)*	1.42 (0.42-4.77)	6.91 (2.70-17.68)*
Lupus anticoagulant	2.97 (1.03-8.56)*	2.38 (0.81-6.70)	1.45 (0.76-2.75)	N/A	N/A
Acquired APCR	4.04 (1.67-9.76)*	0.90 (0.21-3.86)	1.80 (0.70-4.61)	1.25 (0.36-4.37)	N/A
Hyperhomocystinemia	6.25 (1.37-28.42)	0.98 (0.17-5.55)	3.49 (1.21-10.11)*	2.40 (0.36-15.89)	N/A
*Statistically significant Abbreviation: MTHFR, methylene tetrahydrofolate reductase deficiency

Table 2. Management of Pregnancy in a Patient With a History of VTE

Clinical Scenario	Antepartum Management	Postpartum Management
Low-risk thrombophilia without prior VTE	Surveillance without anticoagulation or prophylactic LMWH or UFH	Surveillance without anticoagulation OR postpartum anticoagulation in the presence of additional risk factors (eg, obesity, prolonged immobility, first-degree relative with VTE before age 50 years)
Low-risk thrombophilia with a single episode of VTE in a patient not receiving long-term anticoagulation therapy	Prophylactic or intermediate LMWH/UFH or surveillance without anticoagulation therapy	Anticoagulation therapy or intermediate-dose LMWH/UFH
High-risk thrombophilia (antithrombin deficiency, homozygous factor V Leiden, homozygous prothrombin mutation G20210A, double heterozygous factor V Leiden and prothrombin mutation G20210A) without prior VTE	Prophylactic LMWH or UFH	Anticoagulation therapy
High-risk thrombophilia with previous single episode of VTE in a patient not receiving long-term anticoagulation therapy	Prophylactic-, intermediate-dose, or adjusted-dose LMWH or UFH	Anticoagulation therapy or intermediate- or adjusted-dose LMWH/UFH for 6 weeks
No thrombophilia with single prior episode of VTE with a transient risk factor no longer present and VTE not associated with pregnancy- or estrogen-related risk factor	Surveillance without anticoagulation	Anticoagulation therapy
No thrombophilia with single prior episode of VTE associated with transient risk factor associated with pregnancy or estrogen related	Prophylactic-dose LMWH/UFH	Anticoagulation therapy
No thrombophilia with single prior episode VTE without associated risk factor in a patient not receiving long-term anticoagulation therapy	Prophylactic-dose LMWH/UFH	Anticoagulation therapy
Thrombophilia or no thrombophilia with 2 or more VTE episodes in a patient not receiving long-term anticoagulation therapy	Prophylactic or therapeutic dose of either LMWH or UFH	Anticoagulation therapy or therapeutic dose LMWH/UFH for 6 weeks
Thrombophilia or no thrombophilia with 2 or more VTE episodes in a patient receiving long-term anticoagulation therapy	Therapeutic dose of either LMWH or UFH	Resumption of long-term anticoagulation therapy
Abbreviations: LMWH, low molecular weight heparin; UFH, unfractionated heparin

Back to List

Thrombophilias in Pregnancy Treatment & Management

Approach Considerations

Consultations

Long-Term Monitoring

References

Tables

Contributor Information and Disclosures

What would you like to print?